Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Brown JP, et al. Among authors: hadji p. J Bone Miner Res. 2009 Jan;24(1):153-61. doi: 10.1359/jbmr.0809010. J Bone Miner Res. 2009. PMID: 18767928 Free article. Clinical Trial.
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T; EUROFORS Investigators. Obermayer-Pietsch BM, et al. Among authors: hadji p. J Bone Miner Res. 2008 Oct;23(10):1591-600. doi: 10.1359/jbmr.080506. J Bone Miner Res. 2008. PMID: 18505369 Free article. Clinical Trial.
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC. Eastell R, et al. Among authors: hadji p. J Bone Miner Res. 2009 Apr;24(4):726-36. doi: 10.1359/jbmr.081215. J Bone Miner Res. 2009. PMID: 19049337 Free article. Clinical Trial.
Novel therapies in benign and malignant bone diseases.
Rachner TD, Hadji P, Hofbauer LC. Rachner TD, et al. Among authors: hadji p. Pharmacol Ther. 2012 Jun;134(3):338-44. doi: 10.1016/j.pharmthera.2012.02.005. Epub 2012 Feb 28. Pharmacol Ther. 2012. PMID: 22401778 Review.
[The experiences are uniformly very good].
Hofbauer L, Hadji P. Hofbauer L, et al. Among authors: hadji p. MMW Fortschr Med. 2015 Jul 23;157(13):87. doi: 10.1007/s15006-015-3322-9. MMW Fortschr Med. 2015. PMID: 26206010 German. No abstract available.
Regulation of VEGF by mevalonate pathway inhibition in breast cancer.
Rachner TD, Göbel A, Junker M, Hötzel J, Benad-Mehner P, Hadji P, Hofbauer LC. Rachner TD, et al. Among authors: hadji p. J Bone Oncol. 2013 Jun 7;2(3):110-5. doi: 10.1016/j.jbo.2013.05.003. eCollection 2013 Sep. J Bone Oncol. 2013. PMID: 26909280 Free PMC article.
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.
Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, Jan De Beur S, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S. Cummings SR, et al. Among authors: hadji p. J Bone Miner Res. 2017 Jan;32(1):3-10. doi: 10.1002/jbmr.3039. Epub 2016 Dec 27. J Bone Miner Res. 2017. PMID: 27864889 Free article.
294 results